Here we inserted point mutations into the cusS gene from Escherichia coli K-12 MG1655 using the pORTMAGE recombineering system. We then performed Illumina sequencing and report off-target variants in
CRISPR-Cas genome-editing nucleases hold substantial promise for human therapeutics but identifying unwanted off-target mutations remains an important requirement for clinical translation. For ex vivo
